Trial Profile
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2020
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 16 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2017 Status changed from not yet recruiting to recruiting.